By Devika Patel
Knoxville, Tenn., Dec. 15 - Helicos BioSciences Corp. priced a $6.4 million registered direct offering of units. Thomas Weisel Partners LLC is the bookrunner.
The company will sell 6.4 million units at $1.00 apiece. The units each consist of one common share and one warrant for 0.65 shares, with each whole warrant exercisable at $1.4385 for five years.
Settlement is expected Dec. 21.
Proceeds will be used for research and development and general corporate purposes, including working capital.
Helicos develops instruments and reagents for the high-speed sequencing of DNA and RNA with the highest possible sensitivity. The company is based in Cambridge, Mass.
| Issuer: | Helicos BioSciences Corp.
|
| Issue: | Units of one common share and one warrant for 0.65 shares
|
| Amount: | $6.4 million
|
| Shares: | 6.4 million
|
| Price: | $1.00
|
| Warrants: | One warrant for 0.65 shares per unit
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $1.4385
|
| Bookrunner: | Thomas Weisel Partners LLC
|
| Pricing date: | Dec. 15
|
| Settlement date: | Dec. 21
|
| Stock symbol: | Nasdaq: HLCS
|
| Stock price: | $1.37 at close Dec. 15
|
| Market capitalization: | $100 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
